Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Copolymer-1.

G Comi1, L Moiola

  • 1Neurophysiology Department, San Raffaele Scientific Institute, Milan, Italy.

Bailliere'S Clinical Neurology
|April 2, 1999
PubMed
Summary
This summary is machine-generated.

Copolymer 1 (Cop-1), a synthetic polypeptide mixture, effectively treats multiple sclerosis (MS) by reducing relapses and slowing disability. It demonstrates a good safety profile, making it a viable treatment option for relapsing-remitting MS.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial.

Journal of neurology, neurosurgery, and psychiatry·2011
Same author

Voxelwise assessment of the regional distribution of damage in the brains of patients with multiple sclerosis and fatigue.

AJNR. American journal of neuroradiology·2011
Same author

Thalamic damage predicts the evolution of primary-progressive multiple sclerosis at 5 years.

AJNR. American journal of neuroradiology·2011
Same author

Cortical lesions in children with multiple sclerosis.

Neurology·2011
Same author

Sensorimotor functional connectivity changes in amyotrophic lateral sclerosis.

Cerebral cortex (New York, N.Y. : 1991)·2011
Same author

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.

European journal of neurology·2011
Same journal

Remyelination in demyelinating disease.

Bailliere's clinical neurology·1999
Same journal

Other immunomodulatory therapies in multiple sclerosis.

Bailliere's clinical neurology·1999
Same journal

Interferon beta 1a.

Bailliere's clinical neurology·1999
Same journal

Treatment of multiple sclerosis with interferon beta 1b.

Bailliere's clinical neurology·1999
Same journal

The cause and management of bladder, sexual and bowel symptoms in multiple sclerosis.

Bailliere's clinical neurology·1999
Same journal

Spasticity, ataxia and fatigue in multiple sclerosis.

Bailliere's clinical neurology·1999
See all related articles

Area of Science:

  • Neuroimmunology
  • Autoimmune Diseases
  • Pharmacology

Background:

  • Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • Experimental Autoimmune Encephalomyelitis (EAE) serves as a key animal model for studying MS pathogenesis.
  • Copolymer 1 (Cop-1) is a synthetic polypeptide mixture investigated for immunomodulatory properties.

Purpose of the Study:

  • To evaluate the efficacy and safety of Copolymer 1 (Cop-1) in treating relapsing-remitting multiple sclerosis (MS).
  • To investigate the mechanisms underlying Cop-1's therapeutic effects in MS and its animal model, EAE.

Main Methods:

  • Clinical trials, including a multi-center, randomized, double-blind, placebo-controlled trial.
  • In vitro and in vivo animal studies to assess safety and efficacy.

Related Experiment Videos

  • Magnetic Resonance Imaging (MRI) to monitor disease activity (lesions).

    • Main Results:

    • Cop-1 significantly reduced relapse rates by 29% in a 2-year trial compared to placebo.
    • Cop-1 treatment led to a reduction in new enhancing lesions and lesion load on MRI.
    • Cop-1 demonstrated a favorable safety profile, with minimal side effects and no teratogenic or mutagenic effects.

    Conclusions:

    • Copolymer 1 (Cop-1) is an effective treatment for relapsing-remitting MS, reducing disease activity and disability progression.
    • Cop-1's therapeutic action is attributed to mechanisms like suppressor T-cell induction and competition for antigen presentation.
    • Cop-1 represents a promising therapeutic agent for MS, comparable to interferon beta.